Inhibition of Receptor Activator of NF-κB Ligand by Denosumab Attenuates Vascular Calcium Deposition in Mice

• Published in: The American journal of pathology Vol. 175; no. 2; pp. 473 - 478
• Main Authors: Helas, Susann, Goettsch, Claudia, Schoppet, Michael, Zeitz, Ute, Hempel, Ute, Morawietz, Henning, Kostenuik, Paul J, Erben, Reinhold G, Hofbauer, Lorenz C
• Format: Journal Article
• Language: English
• Published: Bethesda, MD Elsevier Inc 01.08.2009; American Society for Investigative Pathology
• Subjects: Biological and medical sciences; Investigative techniques, diagnostic techniques (general aspects); Medical sciences; Pathology; Pathology. Cytology. Biochemistry. Spectrometry. Miscellaneous investigative techniques; Short Communication; Calcium; Ligand; Rodentia; Denosumab; Vertebrata; Anatomic pathology; Mammalia; Mouse; Activator; Animal; Blood vessel; Inhibitor; Circulatory system; Transcription factor NFκB; Inhibition; Deposition; Biological receptor
• ISSN: 0002-9440; 1525-2191
• DOI: 10.2353/ajpath.2009.080957

Osteoporosis and vascular calcification frequently coincide. A potential mediator of bone metabolism and vascular homeostasis is the triad cytokine system, which consists of receptor activator of nuclear factor-κB (RANK) ligand (RANKL), its receptor RANK, and the decoy receptor osteoprotegerin. Unopposed RANKL activity in osteoprotegerin-deficient mice resulted in osteoporosis and vascular calcification. We therefore analyzed the effects of RANKL inhibition by denosumab, a human monoclonal antibody against RANKL, on vascular calcium deposition following glucocorticoid exposure. Prednisolone pellets were implanted into human RANKL knock-in (huRANKL-KI) mice, which unlike wild-type mice are responsive to denosumab. No histomorphological abnormalities or differences in aortic wall thickness were detected between wild-type and huRANKL-KI mice, regardless of treatment with prednisolone, denosumab, or both. However, concurrent treatment with denosumab reduced aortic calcium deposition of prednisolone-treated huRANKL-KI mice by up to 50%, based on calcium measurement. Of note, aortic calcium deposition in huRANKL-KI mice was correlated negatively with bone mineral density at the lumbar spine ( P = 0.04) and positively with urinary excretion of deoxypyridinoline, a marker of bone resorption ( P = 0.01). In summary, RANKL inhibition by denosumab reduced vascular calcium deposition in glucocorticoid-induced osteoporosis in mice, which is further evidence for the link between the bone and vascular systems. Therefore, the prevention of bone loss by denosumab might also be associated with reduced vascular calcification in certain conditions.